| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.15 | 0.006 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.006 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.13 | 0.007 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | -0.37 | 0.007 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.007 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | -0.082 | 0.008 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.095 | 0.009 |
| mRNA | leptomycin B | CTRPv2 | pan-cancer | AAC | -0.093 | 0.009 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | 0.15 | 0.01 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.098 | 0.01 |